Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell?
Moderna, Pfizer and BioNTech are locked in dispute over the rights to vaccine technology patents.
Moderna (MRNA) reachead $63.94 at the closing of the latest trading day, reflecting a -0.31% change compared to its last close.